Clinical trials: Patients With Bipolar Disorders
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Bipolar Disorder
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.
- Trial name
- NCT00338273
- Testing
- Aripiprazole
- Where
- 8 sites in United States, India
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder, Elderly
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
- Trial name
- NCT01737268
- Testing
- FK949E
- Where
- 32 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Inc
Bipolar I Disorder
Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed
To assess the efficacy and safety of olanzapine in the long-term treatment for patients with bipolar I disorder, depressed.
- Trial name
- NCT00618748
- Testing
- Olanzapine
- Where
- 10 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company
Bipolar Depression
A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
- Trial name
- NCT01986101
- Testing
- SM-13496
- Where
- 8 sites in Japan, Lithuania and 6 more
- Volunteers
- 525 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia, Bipolar 1 Disorder
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
This is a Post-Marketing Surveillance (PMS) of Abilify Maintena® Injections in accordance with Korean regulations on New Drug Re-examination (i.e.
- Trial name
- NCT03386851
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression
This study is aimed to evaluate the bipolar disorder symptoms in patients presented with schizophrenia, schizoaffective disorder or recurrent depression.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Recurrent Depression
- Trial name
- NCT01028196
- Where
- 3 sites in Russia
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Study of Aripiprazole in Patients With Acute Bipolar Mania
The purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.
- Trial name
- NCT00097266
- Testing
- Aripiprazole, Haloperidol
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 615 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Depression
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
The primary objective of this study is to evaluate the superior efficacy of quetiapine extended release(XR) mono-therapy, administered once daily compared to placebo, in the treatment of depressive symptoms in patients with…
- Trial name
- NCT01256177
- Testing
- Quetiapine Fumarate (SEROQUEL) Extended Release
- Where
- 12 sites in China
- Volunteers
- 361 people
- Sponsor
- AstraZeneca
Bipolar Disorder
A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.
- Trial name
- NCT00141271
- Testing
- Geodon (Ziprasidone)
- Where
- 72 sites in United States
- Volunteers
- 536 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania.
- Trial name
- NCT00488618
- Testing
- Cariprazine (RGH-188)
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Forest Laboratories
Bipolar I Disorder
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
The purpose of this study is to evaluate several doses of aripiprazole in patients with bipolar depression.
- Trial name
- NCT00094432
- Testing
- Aripiprazole
- Where
- 40 sites in United States
- Volunteers
- 650 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar I Disorder, Schizophrenia
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
- Trial name
- NCT04127058
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanda Pharmaceuticals
Bipolar Disorder
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Cross - Sectional study requiring one visit at the investigators office for the data collection. Target Group: Patients that suffer from Bipolar Disorder Type 1.
- Trial name
- DIDAXI (NCT00691353)
- Where
- 20 sites in Greece
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
Bipolar Disorders
A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder
The purpose of this NIS is to obtain data on how AAPs are used in DSM-IV-TR Bipolar I and II Disorder, in the course of a major depressive episode.
- Trial name
- HARMONY (NCT00888264)
- Where
- 45 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Bipolar I Disorder
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.
- Trial name
- ANCHOR 150 (NCT00227305)
- Testing
- quetiapine fumarate
- Where
- 48 sites in United States, India and 7 more
- Volunteers
- 381 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Study of Aripiprazole in Patients With a History of Bipolar Disorder
The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with a history of bipolar disorder.
- Trial name
- NCT00036348
- Testing
- Aripiprazole
- Where
- 19 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics